Trial Profile
A Rollover Protocol to Provide Subjects Completing the FTC-203 Study in South Africa With Continued Access to Emtricitabine.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Apr 2018
Price :
$35
*
At a glance
- Drugs Emtricitabine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 21 Feb 2017 Status changed from active, no longer recruiting to completed.
- 17 Sep 2008 New trial record.